IGF-1 LR3
A synthetic long-acting analogue of Insulin-like Growth Factor-1, engineered with a 13-amino acid N-terminal extension and an arginine substitution at position 3. One of the most widely referenced growth factor peptides in in-vitro research, with a significantly extended functional half-life compared to native IGF-1 due to markedly reduced binding affinity for IGF binding proteins (IGFBPs).
For laboratory research use only. Not for human or veterinary use.
Product Overview
IGF-1 LR3 has been extensively referenced in peer-reviewed in-vitro and preclinical literature. Research interest centres on its interactions with IGF-1 receptors and downstream signalling cascades, including the PI3K/Akt and MAPK/ERK pathways, which are implicated in cellular proliferation, protein synthesis, and metabolic regulation. The long-acting analogue format — achieved through structural modifications that reduce binding affinity for IGF binding proteins — makes it a preferred reference compound in experimental models requiring sustained receptor engagement over extended time courses. It is among the most widely studied synthetic growth factor analogues in its class, with a substantial body of published data supporting its use as a reference compound in controlled laboratory settings.
Research Use Only
This product is intended solely for laboratory research applications. Not for human or veterinary use. Not for diagnostic or therapeutic use.
